Skip Navigation


Rheumatology Advance Access originally published online on January 3, 2008
Rheumatology 2008 47(2):188-193; doi:10.1093/rheumatology/kem317
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/2/188    most recent
kem317v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mittendorf, T.
Right arrow Articles by von der Schulenburg, J.-M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mittendorf, T.
Right arrow Articles by von der Schulenburg, J.-M.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective

T. Mittendorf1, B. Dietz2, R. Sterz2, M. A. Cifaldi3, H. Kupper2 and J.-M. von der Schulenburg1

1Center for Health Economics, Leibniz University Hannover, Hannover, 2Abbott GmbH Co KG, Ludwigshafen, Germany and 3Abbott Laboratories, Abbott Park, IL, USA.

Correspondence to: T. Mittendorf, Gottfried Wilhelm Leibniz University Hannover, Center for Health Economics, Koenigsworther Platz 1, D-30167 Hannover, Germany. E-mail: tm{at}ivbl.uni-hannover.de


  Abstract

Objectives. This study evaluated the patients’ perspective of burden of disease among 505 patients with severe, long-standing rheumatoid arthritis receiving adalimumab.

Methods. Health-related quality-of-life and resource use data were collected during a 144-week open-label study.

Results. Adalimumab maintained pain control and reduced the duration of morning stiffness. Work impairment decreased and work productivity was maintained over the duration of the study. Costs were estimated at ~{euro}2100 over the course of the study, and personal help and transportation costs comprised a large percentage of total costs.

Conclusions. These results suggest that adalimumab could improve many aspects of a patient's burden of disease.

KEY WORDS: Rheumatoid arthritis, Patient perspective, Adalimumab, Out-of-pocket payments

Submitted 31 May 2007; revised version accepted 31 October 2007.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.